LightPath Technologies reports fiscal Q3 2026 results on May 14 with a complex setup: short sellers have quietly added to positions over the past month, while the stock jumped 11% on Monday and Canaccord Genuity lifted its target on the same day.
The most striking positioning signal is the recent short interest build. Short interest climbed roughly 20% over the past month to 9.4% of the free float — a meaningful level for a stock this size. The move accelerated in the second half of April, with shares short rising from around 3.4 million to 4.3 million in less than two weeks. Yet the borrow market tells a conflicting story: the cost to borrow is just 0.43% APR, close to a floor rate, and availability is ample at more than 800% of current short interest. That combination — growing short interest alongside an easy borrow — points to orderly, deliberate positioning rather than a squeeze-prone setup.
Options are calm. The put/call ratio of 0.59 is barely above its 20-day average of 0.58, with a z-score close to zero. There is no elevated demand for downside protection heading into the print, which runs counter to what the short interest build might suggest.
The analyst community is constructive — and freshly so. Canaccord Genuity's Austin Moeller raised his price target from $15.50 to $16.50 on May 11, the day before the article, maintaining his Buy rating. That target implies roughly 29% upside from Monday's close of $12.82. Covering analysts across the board have only raised targets over the past year, with Buy ratings throughout. The bull case centers on a $100 million-plus backlog, growing defense and security demand, and the BlackDiamond product gaining ground against traditional Germanium materials. Bears flag dilution risk, customer concentration, and premium valuation — the EV/EBITDA ratio is deeply negative, reflecting pre-profitability status, while the price-to-book of roughly 3.2x is real but not extreme for a growth hardware name.
The ownership picture adds a wrinkle. North Run Capital, a 10% owner with a board seat, sold over $14 million worth of shares between late February and late March at prices between $12.00 and $12.31 — very close to where the stock trades now. That sustained insider selling at current levels is the sharpest counterweight to the analyst optimism. The stock has posted negative reactions after each of its last two earnings events, falling 7% after February's print and 10.6% after the most recent one earlier in May (which appears to be a Q2 event). With short interest at a one-month high and a well-known insider having distributed stock near today's price, Thursday's print is as much a test of whether the backlog is converting into margins as it is a referendum on whether the defense revenue ramp can justify a re-rate from current levels.
See the live data behind this article on ORTEX.
Open LPTH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
